Liverpool, NY

The trials here

What the 2 trials at this site are about, from their registry records.

Conditions

• Diabetic eye disease2 trials

Phase

• Phase 2/32 trials

Status

• Active, not recruiting2 trials

Lead sponsor

• EyeBiotech Ltd.2 trials

Running trials

• Active, not recruiting

  A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

  NCT06957080· Phase 2/3· EyeBiotech Ltd.· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

  NCT06571045· Phase 2/3· EyeBiotech Ltd.· Source